Immatics Biotechnologies completes blank-check deal with Arya Sciences Acquisition Corp., begins trading
July 03, 2020 at 09:29 AM EDT
The clinical-stage biopharmaceutical company, which has its U.S. office near the Texas Medical Center, focuses on the discovery and development of T cell redirecting cancer immunotherapies.
